HCV Treatment
4-Drug Regimen Can Cure Genotype 1 Hepatitis C in 12 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 August 2011 00:00
- Written by Vertex Pharmaceuticals
Interim results from the Phase 2 ZENITH study show that previously untreated people with HCV genotype 1 can achieve sustained response in as little as 12 weeks using a quadruple regimen consisting of telaprevir (Incivek), the experimental HCV polymerase inhibitor VX-222, pegylated interferon, and ribavirin. A newly added arm will evaluate telaprevir, VX-222, and ribavirin without interferon. 
Racial Differences in Eligibility for Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 02 August 2011 00:00
- Written by James Learned
Black hepatitis C patients were significantly more likely to be deemed ineligible for treatment, primarily due to neutropenia and uncontrolled medical conditions, according to a recent study. Less strict neutrophil eligibility criteria and more effective care for chronic diseases would increase access to HCV treatment for black people.
PSI-7977 plus Standard Therapy Cures 100% of Genotype 2-3 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Pharmasset
Pharmasset's investigational hepatitis C virus (HCV) polymerase inhibitor PSI-7977 combined with pegylated interferon/ribavirin cured 100% of people with HCV genotype 2 and 3 in the Phase 2b PROTON trial; sustained response results for hard-to-treat genotype 1 patients are expected later this year.
Injection Drug Users and Adherence to Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Friday, 29 July 2011 00:00
- Written by James Learned
Adherence to hepatitis C treatment was high regardless of injection drug use, a recent Australian study found. Interferon ineffectiveness was primarily driven by discontinuing therapy early rather than skipping doses.
Boceprevir (Victrelis) Approved in Europe
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 20 July 2011 00:00
- Written by Merck
Hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis) received approval from the European Commission, Merck announced this week.
Web Design and Development by